SMi Group's Cancer Vaccines

397 views

Published on

SMi Group's 3rd annual Cancer Vaccines 2014 conference returns to London this September

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
397
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

SMi Group's Cancer Vaccines

  1. 1. CHAIR FOR 2014: Dr Joseph Melenhorst, Director of the Product Development & Correlative Sciences Laboratory, University of Pennsylvania KEY SPEAKERS INCLUDE: • Tom Lillie, Oncology International Therapeutic Head, Amgen • Harpreet Singh, Managing Director, Chief Scientific Officer, Co-Founder, Immatics GmbH • Eric Leire, Chief Executive Officer, DanDrit Biotech • Professor Alex Karlsson-Parra, Chief Scientific Officer, Immunicum • Christian Ottensmeier, Professor in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, University of Southampton • Dr Birgit Scheel, Director Program Management Oncology, CureVac GmbH WHY ATTEND IN 2014: • Insight into a Perfect Partnership – A University of Pennsylvania and Novartis Collaboration! Hear it here first: Assessing techniques involved in removing a patient's T cells and inserting new genetic material to enable the T cells to attack and kill cancer cells • Assessing Oncolytic Vaccines: Reviewing developments from Amgen and Psioxus Therapeutics • What are the key questions in Cancer Immunotherapy? Professor Christian Ottensmeier attacks this question head on! • Evaluating analytical advances for Cancer Vaccines with an insight from Key Opinion Leaders at Immatics GmbH, Vaccinogen and the University of Southampton SMi Presents the 3rd Annual Conference on… 15 - 16 SEPT 2014Holiday Inn Regents Park, London, UK Cancer Vaccines @SMIpharm PLUS AN INTERACTIVE POST-CONFERENCE WORKSHOP Wednesday 17th September 2014, Holiday Inn Regents Park, London, UK Tumour Genomic Heterogeneity in Immunotherapy Workshop Leader: Michael Hanna, Chairman and Chief Executive Officer, Vaccinogen 8.30am – 12.30pm www.cancer-vaccinesevent.com BOOK BY MAY 30TH AND SAVE £300 AND BY JUNE 30TH FOR £100 Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 Quantify Strategies to Enhance Cancer Vaccine Research and Development Sponsored by
  2. 2. Register online at: www.cancer-vaccinesevent.com • Alternatively f Cancer Vaccines Day One | Monday 15th September 2014 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Dr Joseph Melenhorst, Director of the Product Development & Correlative Sciences laboratory, University of Pennsylvania CANCER VACCINE DEVELOPMENT OPENING ADDRESS 9.10 Therapeutic Vaccines for the treatment of Cancer – Where are we now? •Potential of protein based vaccines •A new vector promoting an integrated immune response •Multi-epitopic immune response monitored in the periphery and at the tumor site •Persistent effector T cells Madiha Derouazi, CEO, Amal Therapeutics 9.50 T-VEC – Oncolytic immunotherapy in metastatic melanoma •Reviewing the developments of Oncolytic vaccines for the treatment of cancer •Assessing vaccine delivery – oncolytic virus phase III •Evaluating data from a trial of oncolytic immunotherapy to demonstrate activity in melanoma Tom Lillie, Oncology International Therapeutic Head, Amgen 10.30 Morning Coffee 11.00 Case Study: Oncolytic vaccines – A step into cancer immunotherapy! •Reviewing the developments of Oncolytic vaccines for the treatment of cancer •Assessing vaccine delivery – clinical trial developments John Beadle, CEO, Psioxus Therapeutics 11.40 T cell immune monitoring: reliability, standardisation and use in clinical trials •Validity of assays for use in clinical trials •Data from proficiency panels •Advantages in cancer vaccines and cellular immunotherapies Lisolette Brix, Chief Operational Officer, Immudex 12.20 Networking Lunch 1.30 Cancer vaccination in the era of immunomodulatory immunotherapy •Recent successes with immunomodulatory antibodies raise the question of the necessity for pursuing cancer vaccine development •Immunomodulatory antibodies can only “take the brakes off” immune responses •Cancer vaccines and adoptive immunotherapies will be part of the combination treatments required to cure cancer Graham Pawelec, Professor of Experimental Immunology, University of Tuebingen 2.10 Activated allogeneic DCs as an off-the-shelf vaccine adjuvat in cancer immunotherapy •Immunicum has developed a cellular adjuvant consisting of pre-activated DCs producing high levels of DC- recruiting and DC-activating factors in a sustained fashion •This concept doesn´t require MHC-compatibility between injected cells and the patient and therefore introduces the possibility of using pre-produced and freeze-stored DCs from healthy blood donors as an ”off-the-shelf” vaccine adjuvant •Data from an ongoing phase I/II clinical trial indicate that intratumoral injection (thus using the patient´s own tumor as antigen source) of pre-activated allogeneic DCs is safe and induce a systemic CTL-mediate d anti-tumor response that may prolong survival in patients with metastatic renal cancer Professor Alex Karlsson-Parra, Chief Scientific Officer, Immunicum 2.50 Afternoon Tea 3.20 Phase I/II trial of a novel antibody DNA immunotherapy, SCIB1 ImmunoBody which targets CD64, in the treatment of Melanoma •We demonstrate that SCIB1 is safe •Of 25 evaluable patients, 23 have shown immune responses following repeat dosing with SCIB1 •Detection of objective clinical responses and overall survival times are encouraging Lindy Durrant, Joint CEO, Scancell plc. 4.00 Developments in the Field of Cancer Vaccines - Moving Forward Reserved Speaking Slot Dr. Eric Leire, CEO, DanDrit Biotech 4.40 Chairman's Closing Remarks and Close of Day One Official Media Partner
  3. 3. Want to know how you can get involved? Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162, or email: tarri@smi-online.co.uk Supported by ax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Day Two | Tuesday 16th September 2014 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Dr Joseph Melenhorst, Director of the Product Development & Correlative Sciences laboratory, University of Pennsylvania IMPROVING SUCCESS IN VACCINE RESEARCH & DEVELOPMENT OPENING ADDRESS 9.10 A Perfect Partnership – A University of Pennsylvania and Novartis Collaboration! •Assessing techniques involved in removing a patient's T cells and inserting new genetic material to enable the T cells to attack and kill cancer cells •Is a combination therapy key? •Assessing the modification of cells to infuse back into the patient's body following chemotherapy to fight the remaining tumors Dr Jos Melenhorst, Director of the Product Development & Correlative Sciences laboratory, University of Pennsylvania 9.50 RNActive® for cancer immunotherapy •Targeting immunotherapy candidates for the treatment of cancer by harnessing the natural power of the immune system to fight disease •Current pivotal trials- updates and reviews of the current developments Dr Birgit Scheel, Director Program Management Oncology, CureVac GmbH 10.30 Morning Coffee 11.00 High expectations and harnessing the body’s immune system •Basis for and practical limits of immunotherapies •Pre-clinical models •Clinical progress in cell-based vaccines John Maudsley, CEO, Cancer Vaccines Ltd 11.40 What are the key questions in Cancer Immunotherapy? •Using head and neck cancer squamous cell carcinoma we assess: •Understanding immune event: the importance of where to look •How can we assess the tumour and how can we measure success? •What can we learn from failure? Christian Ottensmeier, Professor in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, University of Southampton 12.20 Networking Lunch ANALYTICAL ADVANCES FOR CANCER VACCINES 1.30 Head and neck cancer immunotherapy: translating laboratory science into a clinical program •Which HNSCC cancers are immunogenic? •What are the attractive targets for (HNSCC) immunotherapy how do we set up the most informative trials how can we optimize the information we gain Dr Emma King, CRUK Senior Lecturer in Head and Neck Surgery, Southampton University 2.10 Biomarker-guided development of novel cancer vaccines - from off-the-shelf to actively personalized •Discovery of novel antigens for cancer immunotherapy using high-throughput mass spectrometry •Biomarker-guided clinical development of such novel antigens in renal, colorectal and brain cancer •Moving beyond current concepts of personalized medicine: actively personalized vaccines in glioma Harpreet Singh, Managing Director, Chief Scientific Officer, Co-Founder, Immatics GmbH 2.50 Afternoon Tea 3.20 The Provacative issue of tumor Genomic Heterogeneity in immunotherapy •The impact in Antigen discovery for Cancer Vaccines •Patient population selection for treatment •In vivo and in vitro monitoring of the treatment and clinical endpoints •Potential for development of epitope based vaccines for treatment and prevention Michael Hanna, Chairman and Chief Executive Officer, Vaccinogen 4.00 DISCUSSION PANEL: Assessing regulatory approval and clinical trial design •What are the implications of manufacturing? •What are the regulatory requirements from phase IIb to III? Panelists: Christian Ottensmeier, Professor in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, University of Southampton John Maudsley, CEO, Cancer Vaccines Ltd Michael Hanna, Chairman and Chief Executive Officer, Vaccinogen 4.40 Chairman’s Closing Remarks and Close of Day Two
  4. 4. Overview of workshop: Science recently highlighted cancer immunotherapy as the “2013 Breakthrough of the Year”. More to the point, they stated "this year marks a turning point in cancer, as long- sought efforts to unleash the immune system against tumors are paying off - even if the future remains a question mark." Most of the celebration involves the compelling results of targeted agents designed to reactivate the immune system by manipulating the PD-1/PD-L1 and CTLA-4 pathways. By blocking these recently identified suppressor molecules, these targeted therapies are designed to unleash the immune system either as monotherapies or in combination with traditional cytotoxic chemotherapy. While these investigations have provided a novel direction for enhancing cancer treatment, additional technologies still need to be developed to specifically identify tumor- associated antigens (TAAs) to harness the full power of the immune system. Active specific immunotherapy (ASI) with cancer vaccines has the potential to be that transformative technology by embracing the recently demonstrated genomic heterogeneity of tumor cells which represent the entire antigenic diversity of each patient’s primary tumor. Why should you attend this workshop: The Provacative Issue of tumor Genomic Heterogeneity in Immunotherapy. • The impact in Antigen discovery for Cancer Vaccines. • Patient population selection for treatment. • In vivo and in vitro monitoring of the treatment and clinical endpoints. • Potential for development of epitope based vaccines for treatment and prevention. HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 17th Septemeber 2014 | 8.30am – 12.30pm | Holiday Inn Regents Park, London, UK Tumour Genomic Heterogeneity in Immunotherapy Workshop Leader: Michael Hanna, Chairman and Chief Executive Officer, Vaccinogen About the workshop host: Michael G. Hanna, Jr., Ph.D. Chairman and Chief Executive Officer, Vaccinogen Dr. Hanna is the founder of Vaccinogen and the discoverer and developer of OncoVAX® an autologous vaccine designed to provoke a specific immune response against colon cancer cells. His previous accomplishments include Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, Chief Operating Officer of Organon Teknika/Biotechnology Research Institute and Sr. Vice President of Organon Teknika Corporation. Prior to that (1975-1982) Dr. Hanna was Director of the National Cancer Institute, Frederick Cancer Research Center. Dr. Hanna received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 11 patents in immunotherapy and has been the recipient of numerous honors, and served on many editorial boards. About the Organisation: Vaccinogen, Inc. is a cancer vaccine company that is clinically testing its OncoVAX® treatment which is designed to prevent the recurrence of colon cancer and potentially other solid tumors. It is a patented process that circumvents the extreme diversity of tumor cells by leveraging a patient’s own live tumor cells to launch a broad immune response against colon cancer. The Company believes that OncoVAX, at an optimum dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in both preventing cancer recurrence after surgical resection of the primary tumor and addressing the diversity of cancer cells. OncoVAX has completed five clinical studies, including a Phase III trial with the optimum dose and regimen. The Company expects to begin a pivotal Phase IIIb trial under an FDA Special Protocol Assessment (SPA) classification in the fourth quarter of 2013. The SEC completed its review of Vaccinogen’s Form 10 registration statement on October 16, 2013. The Company’s shares trade on the OTC.QB under the symbol “VGEN”. More information is available at www.vaccinogeninc.com Sponsored by Immudex provides MHC Dextramer reagents for quantification of antigen-specific T cells, and also provides MHC Multimer and Elispot immune monitoring proficiency panel services. The overall goal is to enable simple, accurate and reliable monitoring of antigen-specific cellular immunity, and to promote the routine use of these technologies in vaccine development. www.immudex.com Scancell is an AIM listed company developing novel treatments for cancer based on its proprietary ImmunoBody® and Moditope® technology platforms which stimulate target specific high avidity T cells. Scancell’s first ImmunoBody®, SCIB1, which is being developed for melanoma, has produced a potent immune response and tumour destruction in late stage patients. www.scancell.co.uk AGENDA: 8.30 Registration and Coffee 9.00 Assessing the impact in Antigen discovery for Cancer Vaccines 10.00 Coffee Break 10.30 Reviewing the patient population selection for treatment 11.30 Evaluating the in vivo/in vitro monitoring of the treatment and clinical endpoints 12.30 Closing of workshop
  5. 5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk JUNE Biobanking 23 - 24 June 2014, London ADMET 30 June - 1 July 2014, London Peptides 30 June - 1 July 2014, London JULY Lyophilisation 7 - 8 July 2014, London BioNetworks 7 - 8 July 2014, London Allergies 9 - 10 July 2014, London Immunogenicity 14 - 15 July 2014, London SEPTEMBER Cancer Vaccines 15 - 16 September 2014, London Biosimilars and Biobetters 29 - 30 September 2014, London OCTOBER European Pharmaceutical Pricing and Reimbursement 13 - 14 October 2014, London Orphan Drugs 20 - 21 October 2014, London COPD: Novel Therapeutics and Management Strategies 20 - 21 October 2014, London Point of Care Diagnostics - Market Opportunities and Technology Trends 27 - 28 October 2014, London NOVEMBER Cell Based Assays 19 - 20 November 2014, London Clinical Trials in CNS 19 - 20 November 2014, London DECEMBER Cold Chain Distribution 2 - 3 December 2014, London SMi'S PHARMACEUTICAL PORTFOLIO 2014 Cancer Vaccines 15th & 16th September 2014A little more about the Chairman Dr Joseph Melenhorst Dr. Melenhorst built his career in human T cell immunology, leukemia biology, immunity and correlative sciences starting with his Ph.D. studies at the Leiden University Medical Center, Leiden, Netherlands, followed by a post- doctoral position and staff scientist position at the National Institutes of Health in Bethesda, Maryland. He studied the immune pathogenesis of the bone marrow failure syndromes aplastic anemia, large granular lymphocyte leukemia and myelodysplastic syndromes, acquiring expertise in advanced techniques such as high-resolution functional flow cytometry and the cellular and molecular dissection of the human T cell repertoire. By combining these skills with the manufacture of polyclonal and clonal T cell lines and exploiting the use of gene-modified activated T cells as antigen presenting cells he prepared himself for a leadership role in the field of cellular therapies and correlative sciences. His expertise is in the in vitro generation and analysis of T cell reactivity with leukemic, viral, and allo-antigens; immune pathogenesis of graft-versus-host disease and immune reconstitution post-transplant and immunotherapy, and his expert opinion is often consulted for the review of manuscripts submitted to high-impact scientific journals such as Blood and the Journal of Immunology. In addition, Dr. Melenhorst has contributed reviews to journals such as Blood, Cytometry, and Cytotherapy. In total Dr. Melenhorst’s publication record consists of over 60 publications, including 10 invited reviews and commentaries in high-impact scientific journals, and six additional research papers from his contributions at the NIH that have been submitted or are in preparation. In August 2012, Dr. Melenhorst was recruited and appointed as Deputy Director of Clinical Cell and Vaccine Production Facility within the Translational Research Program (TRP), Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, and in October of 2013 he assumed the role of Director of a new unit within TRP: the Product Development & Correlative Sciences (PDCS) laboratory. Dr. Melenhorst’s interest in translational research is continued at the PDCS lab on the improvement of the potency of chimeric antigen receptor-expressing T (CART) cells in certain leukemias and solid tumors, the understanding of the in vivo potency of CART cells, and biomarkers of immunotherapy. Dr. Melenhorst is a highly original scientist who has originated and contributed to innovations at the National Institutes of Health and the University of Pennsylvania.
  6. 6. FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK CANCER VACCINES Conference: Monday 15th & 16th September 2014, Holiday Inn Regents Park Hotel, London, UK Workshop: Wednesday 17th September 2014, London 4 WAYS TO REGISTER www.cancer-vaccinesevent.com If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. Unique Reference Number Our Reference LVP-116 Terms and Conditions of Booking DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: Department/Division: Company/Organisation: Email: Company VAT Number: Address: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Mobile: Switchboard: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. ACCOUNTS DEPT Title: Forename: Surname: Email: Address (if different from above): Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: VENUE Holiday Inn, Regents Park, Carburton Street, London, W1W 5EE □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 □ Book by 30th May to receive £300 off the conference price □ Book by 30th June to receive £100 off the conference price EARLY BIRD DISCOUNT Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-116 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 □ Cheque We can only accept Sterling cheques drawn on a UK bank. □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Cardholder’s Name: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): LIVE STREAMING/ON DEMAND/ DOCUMENTATION Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room. Price Total □ Live Streaming £999.00 + VAT (UK) £1198.80 □ On demand £599.00 + VAT (UK) £718.80 (available 24 hours after the event) □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations - paper copy £499.00 - £499.00 (or only £300 if ordered with the Document Portal) PAYMENT VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________________ CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference only £1499.00 +VAT £1798.80 □ Conference and Workshop £2098.00 +VAT £2517.60 □ Workshop only £599.00 +VAT £718.80 PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80 The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.

×